CDC today released comparative effectiveness data for the three COVID-19 vaccines available in the U.S. in individuals without immunocompromising conditions.
The study also found that protection from the Pfizer-BioNTech vaccine dipped four months after vaccination to 77%. The effectiveness of the Moderna vaccine at that interval was 92%.
The CDC also concluded that, from March 11 to August 15, the Moderna vaccine was 93% effective. The Pfizer-BioNTech and Janssen vaccines had lower effectiveness rates of 88% and 71%, respectively. The research also found that post-vaccination anti-spike IgG and anti-RBD IgG antibodies levels were “significantly lower” for Janssen vaccine recipients than those who received mRNA vaccines.
A U.K.-based study published in Nature reached similar conclusions about the durability of protection from the Pfizer–BioNTech and Oxford–AstraZeneca COVID-19 vaccines.
Drawing data from more than 3,600 adults, the study interpreted vaccine efficacy as protection against hospitalization.
The report noted that all three COVID-19 vaccines available in the U.S. prevented hospitalization based on data from 21 hospitals.
In related news, an FDA advisory panel recommended against the use of COVID-19 vaccine boosters in the broader public but supported boosters for those 65 and older and in other high-risk individuals.
Filed Under: Infectious Disease
